Xtant Medical Nabs Patent for Demineralized Bone Matrices

Xtant Medical Holdings Inc. received U.S. patent related to its Bacterin International subsidiary (Xtant recently was formed following Bacterin’s purchase of X-spine Systems—the company reports Bacterin and X-spine as subsidiaries.)
 
The U.S. Patent and Trademark Office has issued Patent No. 9,114,191, titled “Process for Demineralization of Bone Matrix with Preservation of Natural Growth Factors.” The patent covers demineralized bone matrices derived from cortical bone, which include Bacterin’s branded product lines OsteoSTX, OsteoWrap, and OrbitalWrap HD. Bacterin has pending patent applications in the United States to pursue protection on other aspects of its allograft processing and demineralization technologies.
 
“The issuance of this patent confirms Bacterin’s position as a leader in allograft processing innovation,” said Gregory Juda, Bacterin’s chief scientific officer. “This patent adds to the growing body of evidence substantiating the superior processing methodologies associated with Bacterin’s allograft portfolio.”
 
Bacterin’s patented processing technologies are designed to impart improved handling properties to allografts while simultaneously exposing native growth factors that are inherent to natural human bone. The resulting enhanced biologic activity promotes rapid healing via tissue regeneration for patients requiring bone-grafting procedures, according to the company. Company officials report that clinical investigators evaluating Bacterin’s patented demineralized bone grafts have demonstrated fusion rates greater than 97 percent in peer-reviewed, published studies.
 
Xtant Medical Holdings develops products for orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries.